Logo

Bristol Myers-Squibb, Saladax Expand Companion Dx Deal to Include Ortho-Clinical Diagnostics

Sep 21, 2011

NEW YORK (GenomeWeb News) – Bristol Myers-Squibb and Saladax Biomedical today expanded an agreement covering companion diagnostics to include Johnson & Johnson's Ortho-Clinical Diagnostics.

The three firms will collaborate to develop and gain regulatory approval of certain diagnostic assays. Saladax and Ortho-Clinical have a separate agreement to commercialize assays resulting from the deal.

Financial and other terms of both deals were not disclosed.

Saladax and Bristol-Myers Squibb originally reached a partnership in May 2010 to develop clinical diagnostic tests for certain drug compounds in Bristol Myers-Squibb's pipeline. The terms of that deal called for the two firms to collaborate on development and regulatory approvals.

Saladax had exclusive global rights to commercialize assays developed from the collaboration.

Filed under

Diagnostics
BMS
Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.